partnering with rigel

Partnering Approach

We are exploring new opportunities with potential collaborators. Our earliest partnerships focused on the early stages of drug discovery, specifically on target discovery and validation. Rigel has received more than $260M to date in research funding, milestone payments and investments. Our goal is to establish strategic collaborations with pharmaceutical and biotechnology companies; preferably after Phase 2 trials, to develop and market our product candidates.

For information on the above opportunities, contact: